Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Severe asthma Type 2-high is a phenotype characterized by type 2-driven airway inflammation and is associated with elevated inflammatory biomarkers. According to Norihiro Harada et al. (2023), 599 of 732 severe asthma patients (81.8%) had the type 2-high phenotype. According to severe asthma type 2-high epidemiology forecast by Expert Market Research, its prevalence highlights the significant burden of eosinophilic inflammation globally.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Severe Asthma Type 2-High Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of severe asthma type 2-high. It projects the future incidence and prevalence rates of severe asthma type 2-high cases across various populations. The study covers age, gender, and type as major determinants of the severe asthma type 2-high population. The report highlights patterns in the prevalence of severe asthma type 2-high over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of severe asthma type 2-high in the 8 major markets.
Regions Covered
Severe asthma type 2-high is a persistent form of asthma characterized by ongoing type 2 inflammation, involving cytokines such as interleukin-4, interleukin-5, and interleukin-13. This inflammatory pathway is commonly associated with elevated blood or sputum eosinophils, increased fractional exhaled nitric oxide, atopy, or elevated immunoglobulin E. Severe asthma type 2-high can present predominantly as allergic asthma, eosinophilic asthma, or overlapping allergic and eosinophilic disease. Patients may experience persistent symptoms and recurrent exacerbations despite optimized high-dose inhaled corticosteroid-based treatment.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Patients with uncontrolled asthma, recurrent exacerbations, allergic disease, or eosinophilic inflammation |
|
Key Diagnostic Method |
Spirometry, supported by blood eosinophils, fractional exhaled nitric oxide, and immunoglobulin E assessment |
|
Major Risk Factor |
Tobacco smoke exposure and other airway irritants |
|
Major gap in the market |
Underdiagnosis and undertreatment |
The severe asthma type 2-high epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the severe asthma type 2-high epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for severe asthma type 2-high and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
According to Deepak Talwar et al. (2022), asthma affects approximately 235 million people globally, while type 2-high asthma represents a substantial proportion of severe asthma populations. In India, type 2-high asthma accounted for 85% of severe asthma cases. |
|
Gender-Specific Cases of the Disease |
According to Norihiro Harada et al. (2023), females represented 54.9% of patients with type 2-high severe asthma in Japan. Similarly, Tunn Ren Tay et al. (2025) reported that 55.9% of severe asthma patients were female, indicating a substantial female representation. |
|
Age-Specific Cases of the Disease |
As per Norihiro Harada et al. (2023), the mean age of patients with type 2-high severe asthma in Japan was 64.6 years. The findings indicate that type 2-high severe asthma affects predominantly adult and older patient populations. |
|
Ethnicity-Wise Cases of the Disease |
According to Norihiro Harada et al. (2023), 30.6% of Japanese patients with type 2-high severe asthma experienced asthma exacerbations, defined by oral corticosteroid bursts, injectable steroid use, or hospitalization. In the United States, a 2025 U.S. NHANES analysis found that non-Hispanic Black children were more likely to have T2-high asthma compared with the reference population. Among 505 children with asthma, 271 (54%) were classified as T2-high. |
|
Mortality and Survival Analysis of the Disease |
According to Deepak Talwar et al. (2022), more than 80% of asthma deaths globally occur in low- and lower-middle-income countries. Although type 2-high-specific mortality was not reported, severe asthma contributes substantially to the overall asthma burden. |
|
Disease Type |
Prevalence |
|
Allergic (Atopic) Severe Asthma |
Characterized by allergen-driven Type 2 inflammation, with features such as allergic sensitization, elevated immunoglobulin E, and commonly an early-onset disease pattern. |
|
Non-Allergic Eosinophilic Severe Asthma |
Characterized by prominent eosinophilic Type 2 inflammation without a clear external allergic trigger and is commonly associated with an adult-onset disease pattern. |
|
Mixed Allergic-Eosinophilic Severe Asthma |
Characterized by overlapping allergic and eosinophilic inflammatory features, with patients demonstrating characteristics of both allergic sensitization and eosinophilic Type 2 inflammation. |

Read more about this report - Request a Free Sample
The severe asthma type 2-high epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
Epidemiological assessment of severe asthma in the United States includes characterization of type 2 inflammatory phenotypes using biomarkers such as eosinophils, immunoglobulin E, and fractional exhaled nitric oxide. Type 2-high disease represents an important phenotype within severe asthma and is relevant to population-level assessment of inflammatory disease burden. |
|
Germany |
Epidemiological assessment in Germany focuses on the distribution of severe asthma phenotypes and the identification of type 2 inflammatory characteristics within affected populations. Type 2-high severe asthma can be evaluated using inflammatory biomarkers and clinical characteristics relevant to disease stratification. Accordingly, the country-level epidemiological assessment centers on the recognition and characterization of Type 2-high disease within the severe asthma population. |
|
France |
In France, epidemiological assessment of severe asthma includes consideration of type 2 inflammatory patterns and their representation among patients with severe or difficult-to-treat disease. Type 2-high classification is generally linked to identifiable inflammatory characteristics, supporting phenotypic and endotypic assessment of severe asthma populations. |
|
Italy |
In Italy, epidemiological evaluation of type 2-high severe asthma involves characterization of inflammatory phenotypes among patients with severe disease. Type 2-high status provides an epidemiological basis for distinguishing patients according to inflammatory characteristics and understanding the distribution of severe asthma endotypes. |
|
Spain |
Epidemiological assessment of type 2-high severe asthma in Spain focuses on identifying patients with severe disease who demonstrate type 2 inflammatory characteristics. Such assessment supports characterization of the proportion of severe asthma attributable to type 2-high inflammatory patterns and evaluation of disease burden across affected populations. |
|
United Kingdom |
According to Hitasha Rupani et al. (2023), 93% of 388 biologic-naive patients in the Wessex Asthma Cohort of difficult asthma had Type 2-high asthma. Raised peripheral blood eosinophils and fractional exhaled nitric oxide were important components of the type 2-high classification. The study also reported that 96% of a 117-patient subset met the type 2-high definition when sputum eosinophilia was incorporated. These findings demonstrate the substantial representation of type 2-high disease among difficult-to-treat and severe asthma patients in the United Kingdom. |
|
Japan |
According to Norihiro Harada et al. (2023), 599 of 732 severe asthma patients in Japan, equivalent to 81.8%, had Type 2-high asthma. The mean age was 64.6 years, and females accounted for 54.9% of the Type 2-high population. Asthma exacerbations occurred in 30.6% of Type 2-high patients. The same study reported that asthma prevalence in Japan ranges from 6% to 10%, while severe asthma accounts for 2.4% to 12.7% of patients with asthma. |
|
India |
According to Deepak Talwar et al. (2022), approximately 2.4% of India’s population has asthma, while severe asthma is reported in fewer than 10% of adults. The study estimated that approximately 20 million Indians may have severe asthma. Type 2-high asthma accounted for 85% of severe asthma cases, with eosinophilic severe asthma representing 49% and atopic severe asthma 36%. These findings indicate a substantial Type 2-high component within the severe asthma population in India. |
A major epidemiological gap across the covered markets is the identification of patients with uncontrolled asthma who have underlying type 2 inflammation but remain insufficiently phenotyped. Greater use of blood eosinophils, fractional exhaled nitric oxide, immunoglobulin E assessment, and structured severe-asthma evaluation can improve patient identification and treatment stratification. India represents an important opportunity because substantial underdiagnosis and undertreatment of asthma remain challenges. Across developed markets, another opportunity involves improving identification of patients who remain uncontrolled despite standard inhaled therapy and may be candidates for type 2-targeted biologic therapies.
Severe asthma type 2-high treatment focuses on controlling airway inflammation, reducing exacerbations, improving symptom control, and minimizing systemic corticosteroid exposure. Standard management includes optimized inhaled corticosteroid and long-acting beta2-agonist therapy, appropriate inhaler technique, adherence assessment, trigger avoidance, and management of relevant comorbidities. For patients with persistent type 2 inflammation and inadequate disease control, biologic therapy may be added according to the patient's inflammatory phenotype. Type 2-targeted therapies include anti-immunoglobulin E, anti-interleukin-5, anti-interleukin-5 receptor, anti-interleukin-4 receptor alpha, and anti-thymic stromal lymphopoietin therapies.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.